Distinct mutation pathways of non-subtype B HIV-1 during in vitro resistance selection with nonnucleoside reverse transcriptase inhibitors.
about
Screening for and verification of novel mutations associated with drug resistance in the HIV type 1 subtype B(') in ChinaIdentification of the critical sites of NNRTI-resistance in reverse transcriptase of HIV-1 CRF_BC strainsHIV-1 Genetic Variability and Clinical ImplicationsHIV-1 genetic variation and drug resistance development.Drug resistance in non-B subtype HIV-1: impact of HIV-1 reverse transcriptase inhibitors.Human immunodeficiency virus type 1 resistance or cross-resistance to nonnucleoside reverse transcriptase inhibitors currently under development as microbicides.Impact of drug resistance-associated amino acid changes in HIV-1 subtype C on susceptibility to newer nonnucleoside reverse transcriptase inhibitors.Role of HIV Subtype Diversity in the Development of Resistance to Antiviral Drugs.The HEPT Analogue WPR-6 Is Active against a Broad Spectrum of Nonnucleoside Reverse Transcriptase Drug-Resistant HIV-1 Strains of Different Serotypes.Antiviral activity and in vitro mutation development pathways of MK-6186, a novel nonnucleoside reverse transcriptase inhibitorThe Impact of HIV Genetic Polymorphisms and Subtype Differences on the Occurrence of Resistance to Antiretroviral Drugs.An analysis of drug resistance among people living with HIV/AIDS in Shanghai, ChinaConnection subdomain mutations in HIV-1 subtype-C treatment-experienced patients enhance NRTI and NNRTI drug resistanceIn vitro and in vivo activities of AIC292, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor.Are subtype differences important in HIV drug resistance?In vitro characterization of MK-1439, a novel HIV-1 nonnucleoside reverse transcriptase inhibitor.A Phylogenetic Analysis of HIV-1 Sequences in Kiev: Findings among Key Populations.Patterns of HIV-1 Drug-Resistance Mutations among Patients Failing First-Line Antiretroviral Treatment in South India.Mechanistic Study of Common Non-Nucleoside Reverse Transcriptase Inhibitor-Resistant Mutations with K103N and Y181C SubstitutionsNovel Mutations L228I and Y232H Cause Nonnucleoside Reverse Transcriptase Inhibitor Resistance in Combinational PatternIn vitro resistance selection with doravirine (MK-1439), a novel nonnucleoside reverse transcriptase inhibitor with distinct mutation development pathways.In vitro selection of HIV-1 CRF08_BC variants resistant to reverse transcriptase inhibitors.Docking analysis and resistance evaluation of clinically relevant mutations associated with the HIV-1 non-nucleoside reverse transcriptase inhibitors nevirapine, efavirenz and etravirine.Human immunodeficiency virus type 1 drug resistance in a subset of mothers and their infants receiving antiretroviral treatment in Ouagadougou, Burkina Faso
P2860
Q28485108-CE08941B-8AB2-404E-8899-FEC1657F4997Q28537991-265707DE-578D-4FFB-95B8-5DD02D106652Q30352010-EE8EC379-F92E-44B5-8E25-310BA74B3FCBQ30354857-68CED0FE-1134-4BEB-A85B-C90F0165C102Q34303603-C1CF4453-35DB-4B4E-8375-0EF7D5D0AE71Q34737547-93554375-7742-44FE-AC50-F6D907736A18Q35105844-2A51442C-A22F-4045-89A0-E9CCB884958BQ35260403-BB3C7EFC-A2B6-4831-ACB0-F18E529561D8Q35859896-72F3BDD2-5F3E-4055-9CC2-CEA630AB9B2DQ36018893-44A36B3D-FDB8-4953-9BC9-FB30110CE16AQ36077418-AF1DD605-E829-4C2B-9825-4847F1CEC3BBQ36277181-1FBD8B81-8DD1-4A47-81D1-9DFA4282590BQ36501787-D34DF20A-5794-4024-AE18-5A6E9460D2EAQ37263490-72D0BC1F-C7FC-4355-BA39-ACA21EFE8302Q37633109-2B3AB4BC-6D32-4A51-A554-439D15F3A103Q37643598-05C300E4-6924-4F3C-A8F6-81525549434FQ38748311-BE2A7ACF-D73F-41E2-BF69-310DACBAEEC4Q38962278-2268560B-EC55-4D19-BB4C-47C259E46B53Q39350740-68A97865-EF27-462B-B7F6-1FFA32AFA551Q39627546-8E823936-0EEC-4631-89DD-C9E1536C956CQ41668874-CAA44D4E-7A4C-431A-A887-03137A7396F8Q41720036-4E920D57-468E-43F9-A4E8-C4EAA13C4CD3Q46230871-FBC25DA4-F2F1-4E1C-AA13-5C86DC4930C3Q56335908-BF0BC90A-00DD-43B0-BFEA-91FC840A193B
P2860
Distinct mutation pathways of non-subtype B HIV-1 during in vitro resistance selection with nonnucleoside reverse transcriptase inhibitors.
description
2010 nî lūn-bûn
@nan
2010 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2010 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
name
Distinct mutation pathways of ...... erse transcriptase inhibitors.
@ast
Distinct mutation pathways of ...... erse transcriptase inhibitors.
@en
Distinct mutation pathways of ...... erse transcriptase inhibitors.
@nl
type
label
Distinct mutation pathways of ...... erse transcriptase inhibitors.
@ast
Distinct mutation pathways of ...... erse transcriptase inhibitors.
@en
Distinct mutation pathways of ...... erse transcriptase inhibitors.
@nl
prefLabel
Distinct mutation pathways of ...... erse transcriptase inhibitors.
@ast
Distinct mutation pathways of ...... erse transcriptase inhibitors.
@en
Distinct mutation pathways of ...... erse transcriptase inhibitors.
@nl
P2093
P2860
P356
P1476
Distinct mutation pathways of ...... erse transcriptase inhibitors.
@en
P2093
Daria J Hazuda
Georgia B McGaughey
Jay A Grobler
Meiqing Lu
Michael D Miller
Ming-Tain Lai
Peter J Felock
Philip M McKenna
Renee C Hrin
Robert M Tynebor
P2860
P304
P356
10.1128/AAC.00829-10
P407
P577
2010-08-30T00:00:00Z